# Lisinopril + amlodipine

**Indication**: Essential hypertension  
*ICD11 code: BA00.Z*

**INN**: Lisinopril + amlodipine

**Medicine type**: Chemical agent

**List type**: Core

**Formulations**: Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

**EML status history**:  
- First added in 2019 ([TRS 1021](https://www.who.int/medicines/services/trs/))  
- Changed in 2021 ([TRS 1035](https://www.who.int/medicines/services/trs/))

**Sex**: All

**Age**: Adolescents and adults

**Therapeutic alternatives**: Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**: Therapeutic alternatives are medicines in the 4th level ATC chemical subgroups: C09AA ACE inhibitors, plain (for lisinopril) and C08CA Dihydropyridine derivatives (for amlodipine)

**Patent information**: Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**: [Lisinopril + amlodipine](https://en.wikipedia.org/wiki/Lisinopril_amlodipine)

**DrugBank**:  
- [Lisinopril](https://www.drugbank.ca/drugs/DB00297)  
- [Amlodipine](https://www.drugbank.ca/drugs/DB00761)

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that fixed-dose combinations of medicines in 4th level ATC chemical subgroups, C09AA ACE inhibitors, plain (for lisinopril) and C08CA Dihydropyridine derivatives (for amlodipine), be specified as therapeutic alternatives under the square box listing for lisinopril + amlodipine on the EML.